We are delighted to announce the acquisition of a D300e digital distributor from TECAN, a key investment worth 50,000 euros.

This state-of-the-art device will enable our team to carry out high-throughput assays. With its precision and speed, the D300e will not only accelerate the identification of new vulnerabilities, but also enable optimal evaluation of inhibitors and new therapeutic combinations.